Nominate STAT3 development candidate for liquid and solid tumor indications
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 12 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- by 6 Aug 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Nomination of STAT3 development candidate for liquid and solid tumor indications (1H 2021)”
What we found
Evidence strength A What the grades mean
The company identified KT-333 as its lead STAT3 degrader candidate in an August 2021 filing, which occurred after the first half of 2021 deadline.
-
A Kymera Therapeutics, Inc. 8-K filed 2021-08-06
“Kymera’s lead STAT3 degrader candidate, KT-333, is currently in preclinical development.” ✓ confirmed on the page
Market reaction: the shares moved +0.9% against the S&P 500 over the three sessions around the disclosure (5 Aug 2021 to 10 Aug 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Nominate
- Deliverable
- STAT3 development candidate
- Target
- 1 candidate
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Kymera Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-KYMR-021896 · Corrections policy